This is a limited company view. Sign up for a Free Trial to see everything.

Aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. Our lead product candidate ALRN-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins, MDMX and MDM2. The p53 protein is long known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. We believe that ALRN-6924 is the first and only product candidate in clinical development that can disrupt the interaction of both MDMX and MDM2 to restore p53 function as the body's first line of defense against cancer.

B2B
Biotechnology
Cleantech
Healthcare
Pharmaceuticals
Wind Power

Overview

Location

Boston

Founded

2005

Employees

47

Stage

Public

Total funding

$133M

Last funding

3 years ago

Acquisitions

0

Growth score

-92

Mindshare score

-110

Scoring

Employee Growth

Use Aileron Therapeutic's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use Aileron Therapeutic's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial

Key People

Principal Scientist
Clinical Operations
Vice President
serbest
Ev yöneticisi
Executive Assistant
Principle scientist
chargé de production
Manager Business Development
Head of Intellectual Property
customer service
Director
Senior Research Associate

Similar Companies

Gritstone Oncology

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics.
Series B|75 employees

Gain context with Mattermark Salesforce Enrichment

Find out how

Notes